Skip to content
buyModerate

Roivant Sciences Ltd. bought $337M of IMVT

director, owner at Immunovant, Inc.. 16,845,010 shares at an average of $20.00, traded Jan 13, 2025, filed Jan 15, 2025.

Conviction score
46
Value
$337M
16,845,010 shares
Holdings after
96,650,341
+21% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $336.9M at market
    +25
  • Relative to holdings
    Holdings up 21%
    +6
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

IMVTOct 9, 2026 · close 30.47
Since filing Jan 15, 2025: +24.9%SPY +33.9% · excess -9.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001140361-25-001188, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 13, 2025POpen-market purchase
Common Stock, $0.0001 par value per share
+16,845,010$20.00$337M96,650,341Jan 15, 2025

Related signals

Other insiders at Immunovant, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
43Moderate
IMVTsell 4
Immunovant, Inc.
Melanie Gloria
Chief Operating Officer
$72k
2,241 shares
-1%
40Moderate
IMVTsell 4
Immunovant, Inc.
Jay S Stout
Chief Technology Officer
$122k
3,809 shares
-2%
36Weak
IMVTsell 4
Immunovant, Inc.
Christopher Van Tuyl
Chief Legal Officer
$43k
1,327 shares
-1%
35Weak
IMVTsell 4
Immunovant, Inc.
Eric Venker
Chief Executive Officer
$120k
3,506 shares
-1%
40Moderate
IMVTsell 4
Immunovant, Inc.
Christopher Van Tuyl
Chief Legal Officer
$103k
2,846 shares
-2%
23Weak
IMVTsell
Immunovant, Inc.
Christopher Van Tuyl
Chief Legal Officer
$72k
2,877 shares
-2%
29Weak
IMVTsell
Immunovant, Inc.
Melanie Gloria
Chief Operating Officer
$90k
3,238 shares
-2%
22Weak
IMVTsell
Immunovant, Inc.
Jay S Stout
Chief Technology Officer
$51k
1,977 shares
-1%
20Weak
IMVTsell
Immunovant, Inc.
Jay S Stout
Chief Technology Officer
$32k
1,203 shares
-1%
29Weak
IMVTsell
Immunovant, Inc.
Christopher Van Tuyl
Chief Legal Officer
$291k
10,813 shares
-7%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Roivant Sciences Ltd. bought $337M of IMVT | InsiderTell